{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:23Z","timestamp":1793725703829,"version":"4.6.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11883-025-01290-2","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T20:30:24Z","timestamp":1742675424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Managing Dyslipidemia in Chronic Kidney Disease: Implications for Cardiovascular and Renal Risk"],"prefix":"10.1007","volume":"27","author":[{"given":"Panagiotis","family":"Theofilis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayotis K.","family":"Vlachakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rigas G.","family":"Kalaitzidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"9","key":"1290_CR1","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1159\/000518456","volume":"52","author":"P Theofilis","year":"2021","unstructured":"Theofilis P, Vordoni A, Koukoulaki M, Vlachopanos G, Kalaitzidis RG. Dyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives. Am J Nephrol. 2021;52(9):693\u2013701.","journal-title":"Am J Nephrol"},{"issue":"12","key":"1290_CR2","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1161\/ATVBAHA.108.179697","volume":"30","author":"D Steinberg","year":"2010","unstructured":"Steinberg D, Witztum JL. Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(12):2311\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"1290_CR3","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1007\/s10753-020-01229-6","volume":"43","author":"SF Chang","year":"2020","unstructured":"Chang SF, Chang PY, Chou YC, Lu SC. Electronegative LDL Induces M1 Polarization of Human Macrophages Through a LOX-1-Dependent Pathway. Inflammation. 2020;43(4):1524\u201335.","journal-title":"Inflammation"},{"issue":"2","key":"1290_CR4","doi-asserted-by":"publisher","first-page":"H265","DOI":"10.1152\/ajpheart.00509.2016","volume":"312","author":"TC Yang","year":"2017","unstructured":"Yang TC, Chang PY, Lu SC. L5-LDL from ST-elevation myocardial infarction patients induces IL-1beta production via LOX-1 and NLRP3 inflammasome activation in macrophages. Am J Physiol Heart Circ Physiol. 2017;312(2):H265\u201374.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"1290_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0021-9150(96)05842-X","volume":"124","author":"V Anber","year":"1996","unstructured":"Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 1996;124(2):261\u201371.","journal-title":"Atherosclerosis"},{"issue":"11","key":"1290_CR6","doi-asserted-by":"publisher","first-page":"e0241993","DOI":"10.1371\/journal.pone.0241993","volume":"15","author":"L Liou","year":"2020","unstructured":"Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS ONE. 2020;15(11):e0241993.","journal-title":"PLoS ONE"},{"issue":"3","key":"1290_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/09674845.2012.12069133","volume":"69","author":"M Chu","year":"2012","unstructured":"Chu M, Wang AY, Chan IH, Chui SH, Lam CW. Serum small-dense LDL abnormalities in chronic renal disease patients. Br J Biomed Sci. 2012;69(3):99\u2013102.","journal-title":"Br J Biomed Sci"},{"issue":"1","key":"1290_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12882-016-0358-8","volume":"17","author":"H Shen","year":"2016","unstructured":"Shen H, Xu Y, Lu J, Ma C, Zhou Y, Li Q, et al. Small dense low-density lipoprotein cholesterol was associated with future cardiovascular events in chronic kidney disease patients. BMC Nephrol. 2016;17(1):143.","journal-title":"BMC Nephrol"},{"issue":"12","key":"1290_CR9","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1161\/ATVBAHA.124.321387","volume":"44","author":"D Elias-Lopez","year":"2024","unstructured":"Elias-Lopez D, Vedel-Krogh S, Kobylecki CJ, Wadstrom BN, Nordestgaard BG. Impaired Renal Function With Higher Remnant Cholesterol Related to Risk of Atherosclerotic Cardiovascular Disease: A Cohort Study. Arterioscler Thromb Vasc Biol. 2024;44(12):2647\u201358.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1290_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/IJNRD.S101808","volume":"10","author":"I Mikolasevic","year":"2017","unstructured":"Mikolasevic I, Zutelija M, Mavrinac V, Orlic L. Dyslipidemia in patients with chronic kidney disease: etiology and management. Int J Nephrol Renovasc Dis. 2017;10:35\u201345.","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"1","key":"1290_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2215\/CJN.07320619","volume":"15","author":"JA Lamprea-Montealegre","year":"2020","unstructured":"Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, et al. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. Clin J Am Soc Nephrol: CJASN. 2020;15(1):47\u201360.","journal-title":"Clin J Am Soc Nephrol: CJASN"},{"issue":"23","key":"1290_CR12","doi-asserted-by":"publisher","first-page":"e022988","DOI":"10.1161\/JAHA.121.022988","volume":"10","author":"M Soohoo","year":"2021","unstructured":"Soohoo M, Hashemi L, Hsiung JT, Moradi H, Budoff MJ, Kovesdy CP, et al. Risk of atherosclerotic cardiovascular disease and nonatherosclerotic cardiovascular disease hospitalizations for triglycerides across chronic kidney disease stages among 2.9 million US veterans. J Am Heart Assoc. 2021;10(23):e022988.","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"1290_CR13","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1290_CR14","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1194\/jlr.R083626","volume":"59","author":"JC Hopewell","year":"2018","unstructured":"Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res. 2018;59(4):577\u201385.","journal-title":"J Lipid Res"},{"issue":"7","key":"1290_CR15","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/14728222.2019.1620206","volume":"23","author":"M Bermudez-Lopez","year":"2019","unstructured":"Bermudez-Lopez M, Forne C, Amigo N, Bozic M, Arroyo D, Bretones T, et al. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. Expert Opin Ther Targets. 2019;23(7):619\u201330.","journal-title":"Expert Opin Ther Targets"},{"issue":"8","key":"1290_CR16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","volume":"119","author":"P Pantelidis","year":"2023","unstructured":"Pantelidis P, Oikonomou E, Lampsas S, Zakynthinos GE, Lysandrou A, Kalogeras K, et al. Lipoprotein(a) and calcific aortic valve disease initiation and progression: a systematic review and meta-analysis. Cardiovasc Res. 2023;119(8):1641\u201355.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"1290_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/molecules28030969","volume":"28","author":"S Lampsas","year":"2023","unstructured":"Lampsas S, Xenou M, Oikonomou E, Pantelidis P, Lysandrou A, Sarantos S, et al. Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment. Molecules. 2023;28(3):969.","journal-title":"Molecules"},{"issue":"10","key":"1290_CR18","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","volume":"37","author":"A Bajaj","year":"2017","unstructured":"Bajaj A, Damrauer SM, Anderson AH, Xie D, Budoff MJ, Go AS, et al. Lipoprotein(a) and Risk of Myocardial Infarction and Death in Chronic Kidney Disease: Findings From the CRIC Study (Chronic Renal Insufficiency Cohort). Arterioscler Thromb Vasc Biol. 2017;37(10):1971\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"1290_CR19","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/joim.20027","volume":"296","author":"I Gruber","year":"2024","unstructured":"Gruber I, Kollerits B, Forer L, Di Maio S, Schachtl-Riess JF, Kheirkhah A, et al. Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: results from the german chronic kidney disease study. J Intern Med. 2024;296(6):510\u201326.","journal-title":"J Intern Med"},{"issue":"6","key":"1290_CR20","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40620-023-01590-3","volume":"36","author":"L Barbagelata","year":"2023","unstructured":"Barbagelata L, Masson W, Corral P, Lavalle-Cobo A, Nogueira JP, Rosa DG. Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies. J Nephrol. 2023;36(6):1549\u201359.","journal-title":"J Nephrol"},{"issue":"9","key":"1290_CR21","doi-asserted-by":"publisher","first-page":"100610","DOI":"10.1016\/j.jlr.2024.100610","volume":"65","author":"Y Jiang","year":"2024","unstructured":"Jiang Y, Zhu X, Jordan K, Li Y, Conley S, Tang H, et al. Dyslipidemia-induced renal fibrosis related to ferroptosis and endoplasmic reticulum stress. J Lipid Res. 2024;65(9):100610.","journal-title":"J Lipid Res"},{"issue":"11","key":"1290_CR22","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.5551\/jat.64625","volume":"31","author":"M Seki","year":"2024","unstructured":"Seki M, Nakano T, Tanaka S, Kitamura H, Hiyamuta H, Ninomiya T, et al. Associations between the serum triglyceride level and kidney outcome in patients with chronic kidney disease: the fukuoka kidney disease registry study. J Atheroscler Thromb. 2024;31(11):1556\u201370.","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"1290_CR23","doi-asserted-by":"publisher","first-page":"e0299605","DOI":"10.1371\/journal.pone.0299605","volume":"19","author":"B Weon","year":"2024","unstructured":"Weon B, Jang Y, Jo J, Jin W, Ha S, Ko A, et al. Association between dyslipidemia and the risk of incident chronic kidney disease affected by genetic susceptibility: Polygenic risk score analysis. PLoS ONE. 2024;19(4):e0299605.","journal-title":"PLoS ONE"},{"key":"1290_CR24","doi-asserted-by":"publisher","first-page":"111639","DOI":"10.1016\/j.diabres.2024.111639","volume":"210","author":"SY Jang","year":"2024","unstructured":"Jang SY, Kang M, Song E, Jang A, Choi KM, Baik SH, et al. Remnant cholesterol is an independent risk factor for the incidence of chronic kidney disease in newly-diagnosed type 2 diabetes: A nationwide population-based study. Diabetes Res Clin Pract. 2024;210:111639.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1290_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12944-024-02050-y","volume":"23","author":"HN Jung","year":"2024","unstructured":"Jung HN, Huh JH, Roh E, Han KD, Kang JG, Lee SJ, et al. High remnant-cholesterol levels increase the risk for end-stage renal disease: a nationwide, population-based, cohort study. Lipids Health Dis. 2024;23(1):165.","journal-title":"Lipids Health Dis"},{"issue":"24","key":"1290_CR26","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1016\/j.jacc.2024.08.059","volume":"84","author":"S Bay Simony","year":"2024","unstructured":"Bay Simony S, Rorbaek Kamstrup P, Bodtker Mortensen M, Afzal S, Gronne Nordestgaard B, Langsted A. High Lipoprotein(a) as a Cause of Kidney Disease: A Population-Based Mendelian Randomization Study. J Am Coll Cardiol. 2024;84(24):2407\u201310.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"1290_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000330355","volume":"34","author":"RG Kalaitzidis","year":"2011","unstructured":"Kalaitzidis RG, Elisaf MS. The role of statins in chronic kidney disease. Am J Nephrol. 2011;34(3):195\u2013202.","journal-title":"Am J Nephrol"},{"issue":"15","key":"1290_CR28","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","volume":"51","author":"J Shepherd","year":"2008","unstructured":"Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51(15):1448\u201354.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1290_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","volume":"53","author":"MJ Koren","year":"2009","unstructured":"Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, et al. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53(5):741\u201350.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1290_CR30","doi-asserted-by":"publisher","first-page":"8951","DOI":"10.1038\/s41598-019-45431-5","volume":"9","author":"F Herrera-Gomez","year":"2019","unstructured":"Herrera-Gomez F, Chimeno MM, Martin-Garcia D, Lizaraso-Soto F, Maurtua-Briseno-Meiggs A, Grande-Villoria J, et al. Cholesterol-lowering treatment in chronic kidney disease: multistage pairwise and network meta-analyses. Sci Rep. 2019;9(1):8951.","journal-title":"Sci Rep"},{"issue":"24","key":"1290_CR31","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","volume":"34","author":"W Hou","year":"2013","unstructured":"Hou W, Lv J, Perkovic V, Yang L, Zhao N, Jardine MJ, et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J. 2013;34(24):1807\u201317.","journal-title":"Eur Heart J"},{"issue":"4","key":"1290_CR32","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/cpt.1859","volume":"108","author":"YC Lin","year":"2020","unstructured":"Lin YC, Lai TS, Wu HY, Chou YH, Chiang WC, Lin SL, et al. Effects and Safety of Statin and Ezetimibe Combination Therapy in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2020;108(4):833\u201343.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"1290_CR33","first-page":"CD007784","volume":"11","author":"DJ Tunnicliffe","year":"2023","unstructured":"Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023;11(11):CD007784.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"1290_CR34","doi-asserted-by":"publisher","first-page":"e2346373","DOI":"10.1001\/jamanetworkopen.2023.46373","volume":"6","author":"O Barayev","year":"2023","unstructured":"Barayev O, Hawley CE, Wellman H, Gerlovin H, Hsu W, Paik JM, et al. Statins, mortality, and major adverse cardiovascular events among US veterans with chronic kidney disease. JAMA Netw Open. 2023;6(12):e2346373.","journal-title":"JAMA Netw Open"},{"key":"1290_CR35","doi-asserted-by":"publisher","first-page":"119042","DOI":"10.1016\/j.atherosclerosis.2024.119042","volume":"399","author":"CL Yen","year":"2024","unstructured":"Yen CL, Fan PC, Lee CC, Chen JJ, Chen CY, Tu YR, et al. The role of maintaining lower LDL-C level during statin treatment for advanced CKD patients. Atherosclerosis. 2024;399:119042.","journal-title":"Atherosclerosis"},{"key":"1290_CR36","unstructured":"Iyalomhe OE, Don Nalin Samandika Saparamadu AA, Alexander GC. Use of Statins for Primary Prevention Among Individuals with CKD in the United States: a cross-sectional, time-trend analysis. Am J Kidney Dis. 2024."},{"issue":"1","key":"1290_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"6","key":"1290_CR38","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.2215\/CJN.09121010","volume":"6","author":"W Marz","year":"2011","unstructured":"Marz W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol\u202f: CJASN. 2011;6(6):1316\u201325.","journal-title":"Clin J Am Soc Nephrol : CJASN"},{"issue":"6","key":"1290_CR39","doi-asserted-by":"publisher","first-page":"e182311","DOI":"10.1001\/jamanetworkopen.2018.2311","volume":"1","author":"E Streja","year":"2018","unstructured":"Streja E, Gosmanova EO, Molnar MZ, Soohoo M, Moradi H, Potukuchi PK, et al. Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation. JAMA Netw Open. 2018;1(6):e182311.","journal-title":"JAMA Netw Open"},{"issue":"9784","key":"1290_CR40","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392.","journal-title":"Lancet"},{"issue":"5","key":"1290_CR41","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1053\/j.ajkd.2007.07.023","volume":"50","author":"AS Goldfarb-Rumyantzev","year":"2007","unstructured":"Goldfarb-Rumyantzev AS, Habib AN, Baird BC, Barenbaum LL, Cheung AK. The association of lipid-modifying medications with mortality in patients on long-term peritoneal dialysis. Am J Kidney Dis. 2007;50(5):791\u2013802.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1290_CR42","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/MCA.0000000000001375","volume":"35","author":"K Dimitriadis","year":"2024","unstructured":"Dimitriadis K, Theofilis P, Iliakis P, Pyrpyris N, Dri E, Sakalidis A, et al. Management of dyslipidemia in coronary artery disease: the present and the future. Coron Artery Dis. 2024;35(6):516\u201324.","journal-title":"Coron Artery Dis"},{"key":"1290_CR43","doi-asserted-by":"publisher","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky SL, Newton RS, Day EA, Ford RJ, Lhotak S, Austin RC, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Commun. 2016;7:13457.","journal-title":"Nature Commun"},{"issue":"15","key":"1290_CR44","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","volume":"388","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353\u201364.","journal-title":"N Engl J Med"},{"issue":"4","key":"1290_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S2213-8587(24)00063-9","volume":"12","author":"KK Ray","year":"2024","unstructured":"Ray KK, Bloedon L, Li N, Nissen SE. Evaluating the effect of bempedoic acid on kidney function: call for cautious implementation - Authors\u2019 reply. Lancet Diabetes Endocrinol. 2024;12(4):228\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"1290_CR46","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1111\/dom.15815","volume":"26","author":"YY Hyun","year":"2024","unstructured":"Hyun YY, Kim KS, Hong S, Han K, Park CY. Fenofibrate and risk of end-stage renal disease: A nationwide cohort study. Diabetes Obes Metab. 2024;26(10):4583\u201390.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1290_CR47","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1093\/ndt\/gfad248","volume":"39","author":"H Goto","year":"2024","unstructured":"Goto H, Iseri K, Hida N. Fibrates and the risk of cardiovascular outcomes in chronic kidney disease patients. Nephrol Dial Transplant. 2024;39(6):1016\u201322.","journal-title":"Nephrol Dial Transplant"},{"key":"1290_CR48","doi-asserted-by":"publisher","first-page":"121590","DOI":"10.1016\/j.lfs.2023.121590","volume":"321","author":"Y Horinouchi","year":"2023","unstructured":"Horinouchi Y, Murashima Y, Yamada Y, Yoshioka S, Fukushima K, Kure T, et al. Pemafibrate inhibited renal dysfunction and fibrosis in a mouse model of adenine-induced chronic kidney disease. Life Sci. 2023;321:121590.","journal-title":"Life Sci"},{"issue":"3","key":"1290_CR49","doi-asserted-by":"publisher","first-page":"473","DOI":"10.4093\/dmj.2023.0370","volume":"48","author":"R Izumihara","year":"2024","unstructured":"Izumihara R, Nomoto H, Kito K, Yamauchi Y, Omori K, Shibayama Y, et al. Switching from Conventional Fibrates to Pemafibrate Has Beneficial Effects on the Renal Function of Diabetic Subjects with Chronic Kidney Disease. Diabetes Metab J. 2024;48(3):473\u201381.","journal-title":"Diabetes Metab J"},{"issue":"4","key":"1290_CR50","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s10157-023-02322-4","volume":"27","author":"M Seki","year":"2023","unstructured":"Seki M, Nakano T, Tanaka S, Matsukuma Y, Funakoshi K, Ohkuma T, et al. Design and methods of an open-label, randomized controlled trial to evaluate the effect of pemafibrate on proteinuria in CKD patients (PROFIT-CKD). Clin Exp Nephrol. 2023;27(4):358\u201364.","journal-title":"Clin Exp Nephrol"},{"key":"1290_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.phrs.2019.03.021","volume":"143","author":"M Casula","year":"2019","unstructured":"Casula M, Olmastroni E, Boccalari MT, Tragni E, Pirillo A, Catapano AL. Cardiovascular events with PCSK9 inhibitors: an updated meta-analysis of randomised controlled trials. Pharmacol Res. 2019;143:143\u201350.","journal-title":"Pharmacol Res"},{"issue":"23","key":"1290_CR52","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73(23):2961\u201370.","journal-title":"J Am Coll Cardiol"},{"issue":"42","key":"1290_CR53","doi-asserted-by":"publisher","first-page":"4114","DOI":"10.1093\/eurheartj\/ehaa498","volume":"41","author":"J Tunon","year":"2020","unstructured":"Tunon J, Steg PG, Bhatt DL, Bittner VA, Diaz R, Goodman SG, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020;41(42):4114\u201323.","journal-title":"Eur Heart J"},{"issue":"3","key":"1290_CR54","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/cpdd.650","volume":"8","author":"E Lee","year":"2019","unstructured":"Lee E, Gibbs JP, Emery MG, Block G, Wasserman SM, Hamilton L, et al. Influence of Renal Function on Evolocumab Exposure, Pharmacodynamics, and Safety. Clin Pharmacol Drug Dev. 2019;8(3):281\u20139.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1290_CR55","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mayocp.2019.08.021","volume":"95","author":"RS Wright","year":"2020","unstructured":"Wright RS, Collins MG, Stoekenbroek RM, Robson R, Wijngaard PLJ, Landmesser U, et al. Effects of renal impairment on the pharmacokinetics, efficacy, and safety of inclisiran: an analysis of the ORION-7 and ORION-1 studies. Mayo Clin Proc. 2020;95(1):77\u201389.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1290_CR56","doi-asserted-by":"publisher","first-page":"F48","DOI":"10.1152\/ajprenal.00065.2024","volume":"328","author":"S Hummelgaard","year":"2025","unstructured":"Hummelgaard S, Hvid H, Birn H, Glerup S, Tom N, Bilgin M, et al. Lack of renoprotective effects by long-term PCSK9 and SGLT2 inhibition using alirocumab and empagliflozin in obese ZSF1 rats. Am J Physiol Renal Physiol. 2025;328(1):F48\u201367.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"1290_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5500\/wjt.v6.i1.125","volume":"6","author":"A Agarwal","year":"2016","unstructured":"Agarwal A, Prasad GV. Post-transplant dyslipidemia: Mechanisms, diagnosis and management. World J Transplant. 2016;6(1):125\u201334.","journal-title":"World J Transplant"},{"issue":"2","key":"1290_CR58","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.amjcard.2018.09.037","volume":"123","author":"MLF Co","year":"2019","unstructured":"Co MLF, Agdamag AC, Co MZ, Hertl M, Mohamedali B. Intensity-dependent benefit of statins in survival among prospective kidney transplant patients. Am J Cardiol. 2019;123(2):254\u20139.","journal-title":"Am J Cardiol"},{"issue":"1","key":"1290_CR59","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12944-024-02276-w","volume":"23","author":"I Bellos","year":"2024","unstructured":"Bellos I, Lagiou P, Benetou V, Marinaki S. Efficacy and safety of statin therapy in kidney transplant recipients: a systematic review and meta-analysis. Lipids Health Dis. 2024;23(1):293.","journal-title":"Lipids Health Dis"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01290-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-025-01290-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-025-01290-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T12:41:59Z","timestamp":1742733719000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-025-01290-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1007\/s11883-025-01290-2","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"10 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"41"}}